{"id":"leflunomide-plus-methotrexate","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leflunomide is a disease-modifying antirheumatic drug (DMARD) that blocks pyrimidine synthesis, preferentially affecting activated lymphocytes. Methotrexate is a folate antagonist that inhibits nucleotide synthesis and has immunosuppressive effects. The combination provides synergistic immunosuppression by targeting complementary pathways in cell proliferation and inflammation.","oneSentence":"This combination uses leflunomide to inhibit dihydroorotate dehydrogenase (reducing pyrimidine synthesis) and methotrexate to inhibit dihydrofolate reductase, together suppressing T-cell proliferation and inflammatory cytokine production in autoimmune disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:33:53.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Active rheumatoid arthritis inadequately responsive to monotherapy"}]},"trialDetails":[{"nctId":"NCT07497282","phase":"PHASE2","title":"Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-03-26","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT07428551","phase":"PHASE4","title":"Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients","status":"COMPLETED","sponsor":"Bangladesh Medical University","startDate":"2024-03-01","conditions":"Juvenile Idiopathic Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Refractory Polyarticular Juvenile Idiopathic Arthritis","enrollment":50},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT05671497","phase":"PHASE2, PHASE3","title":"The Effect of Cilostazol on Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT03649061","phase":"PHASE4","title":"COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA","status":"COMPLETED","sponsor":"P. Verschueren","startDate":"2018-06-08","conditions":"Arthritis, Rheumatoid","enrollment":276},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT03531073","phase":"","title":"Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-04-18","conditions":"Psoriatic Arthritis","enrollment":446},{"nctId":"NCT06753565","phase":"PHASE2","title":"L-carnitine Supplementation in Rheumatoid Arthritis Patients","status":"RECRUITING","sponsor":"German University in Cairo","startDate":"2024-12-31","conditions":"Rheumatoid Arthritis (RA)","enrollment":60},{"nctId":"NCT06640309","phase":"PHASE2","title":"The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2023-12-02","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT05458531","phase":"","title":"Monitoring of Inflammatory Conditions","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2022-06-28","conditions":"Inflammatory Disease, Crohn Disease, Ulcerative Colitis","enrollment":664},{"nctId":"NCT05447520","phase":"PHASE2","title":"Montelukast Use in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Noha Mansour","startDate":"2021-12-15","conditions":"Rheumatoid Arthritis","enrollment":92},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT01619176","phase":"NA","title":"Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood","status":"COMPLETED","sponsor":"Chinese Academy of Sciences","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":10},{"nctId":"NCT05871086","phase":"PHASE2, PHASE3","title":"Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Nourhan Elsherif","startDate":"2023-05-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT05626348","phase":"PHASE4","title":"The Clinical Efficacy of Immunomodulators in RA Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-12-22","conditions":"Arthritis, Rheumatoid","enrollment":400},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT05424393","phase":"","title":"Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-04","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT04434118","phase":"","title":"Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-03-20","conditions":"Rheumatoid Arthritis, COVID","enrollment":""},{"nctId":"NCT03449758","phase":"PHASE4","title":"Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-05","conditions":"Rheumatoid Arthritis","enrollment":84},{"nctId":"NCT04124861","phase":"NA","title":"Withdraw Drug in Stable IgG4-Related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-06-23","conditions":"Autoimmune Diseases","enrollment":138},{"nctId":"NCT02930343","phase":"PHASE3","title":"Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2016-09","conditions":"Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT04927000","phase":"PHASE4","title":"The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-05-31","conditions":"Rheumatoid Arthritis","enrollment":170},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT03797872","phase":"PHASE4","title":"Psoriatic Oligoarthritis Intervention With Symptomatic thErapy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-04-17","conditions":"Psoriatic Arthritis","enrollment":1},{"nctId":"NCT04752748","phase":"","title":"Power Doppler in Hand Joints of Early RA Patients","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2014-08","conditions":"Early Rheumatoid Arthritis","enrollment":48},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT02644499","phase":"PHASE4","title":"Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2015-12-31","conditions":"Rheumatoid Arthritis","enrollment":186},{"nctId":"NCT04066803","phase":"PHASE4","title":"Optimal MTX Dose With Folic Acid Randomized Case-control Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-08-01","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT00476996","phase":"PHASE3","title":"A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-05-15","conditions":"Rheumatoid Arthritis","enrollment":836},{"nctId":"NCT03863405","phase":"PHASE2","title":"Metformin Use in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-01-09","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT03736044","phase":"NA","title":"Reconstitution of CD4+CD25highCD127low/-Tcell","status":"COMPLETED","sponsor":"University Hospital of Ferrara","startDate":"2013-11-25","conditions":"Rheumatoid Arthritis","enrollment":48},{"nctId":"NCT01399281","phase":"","title":"Pharmacovigilance in Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents and/or Methotrexate","status":"UNKNOWN","sponsor":"Istituto Giannina Gaslini","startDate":"2011-12","conditions":"Juvenile Idiopathic Arthritis","enrollment":9000},{"nctId":"NCT01709578","phase":"PHASE3","title":"To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":546},{"nctId":"NCT01768572","phase":"PHASE3","title":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":202},{"nctId":"NCT02057250","phase":"PHASE3","title":"To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"RA","enrollment":217},{"nctId":"NCT00521924","phase":"PHASE3","title":"Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":8},{"nctId":"NCT01033656","phase":"PHASE2","title":"Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study","status":"COMPLETED","sponsor":"University of Helsinki","startDate":"2005-12","conditions":"Adult-Onset Still's Disease","enrollment":23},{"nctId":"NCT01313208","phase":"PHASE4","title":"Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":210},{"nctId":"NCT01225393","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":211},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT01834157","phase":"","title":"Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Prof. Laszlo Czirjak","startDate":"2013-04","conditions":"Systemic Sclerosis, Arthritis","enrollment":160},{"nctId":"NCT01600521","phase":"NA","title":"A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2004-11","conditions":"Rheumatoid Arthritis","enrollment":1748},{"nctId":"NCT01749787","phase":"PHASE1","title":"Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Protalex, Inc.","startDate":"2012-11","conditions":"Arthritis, Rheumatoid","enrollment":61},{"nctId":"NCT01659242","phase":"PHASE4","title":"Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study","status":"TERMINATED","sponsor":"Singapore General Hospital","startDate":"2012-07","conditions":"Rheumatoid Arthritis","enrollment":1},{"nctId":"NCT02275299","phase":"PHASE4","title":"Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT00720798","phase":"PHASE3","title":"An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-09","conditions":"Rheumatoid Arthritis","enrollment":2067},{"nctId":"NCT01646385","phase":"","title":"Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":6393},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016},{"nctId":"NCT00230035","phase":"PHASE2","title":"Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT01617590","phase":"NA","title":"Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research","status":"UNKNOWN","sponsor":"Shanxi Medical University","startDate":"2012-05","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT00124982","phase":"PHASE3","title":"Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1286},{"nctId":"NCT00706797","phase":"PHASE4","title":"Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT01211834","phase":"PHASE3","title":"Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT00422227","phase":"PHASE4","title":"Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT00563849","phase":"PHASE4","title":"Leflunomide + Methotrexate in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-05","conditions":"Rheumatoid Arthritis","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Leflunomide plus Methotrexate","genericName":"Leflunomide plus Methotrexate","companyName":"Bangladesh Medical University","companyId":"bangladesh-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses leflunomide to inhibit dihydroorotate dehydrogenase (reducing pyrimidine synthesis) and methotrexate to inhibit dihydrofolate reductase, together suppressing T-cell proliferation and inflammatory cytokine production in autoimmune disease. Used for Rheumatoid arthritis, Active rheumatoid arthritis inadequately responsive to monotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}